Objective: To evaluate sample quality, prostate cancer detection rate and biopsy morbidity in transrectal ultrasound (TRUS)-guided prostate biopsy (PBx) using 16- or 18-gauge Tru-Cut needles. Patients and Methods: Patients undergoing TRUS PBx were consecutively randomized with a 1:1 ratio into two study arms: group A (16-gauge needle) and group B (18-gauge needle). Core fragmentation and small specimen length (<10 mm) rate were the sample quality criteria. Three consecutive visual analog scale tests for pain and the Clavien surgical classification complications grading for rectal bleeding were used to evaluate TRUS PBx morbidity. Results: Overall, 250 patients were evaluated. No statistically significant difference between 16- and 18-gauge biopsy needles was recorded for cancer detection rate (29.6 vs. 30.4%, p = 0.890), core fragmentation rate (5 vs. 7%, p = 0.425) and shorter specimen (2 vs. 2%, p = 0.309). Pain control was similar in the two groups during the biopsy, 30 min after biopsy and the evening of the same day. Very small or absent bleeding was the more frequent complication observed in each group. Conclusion: Prostate detection rate and sample quality were not influenced by needle size. A 16-gauge needle biopsy does not increase TRUS PBx morbidity.

Keywords:
Prostate cancer, Needle biopsy, Prostate biopsy, Sample quality
1.
Heidenreich A, Bellmunt J, Bolla M, et al: EAU guidelines on prostate cancer. Part 1. Screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011;59:61–71.
2.
Ochiai A, Babaian RJ: Review Update on prostate biopsy technique. Curr Opin Urol 2004;14:157–162.
3.
Autorino R, De Sio M, Di Lorenzo G, et al: How to decrease pain during transrectal ultrasound-guided prostate biopsy: a look at the literature. J Urol 2005;174:2091–2097.
4.
Saredi G, Sighinolfi MC, Fidanza F, et al: Does needle caliber affect pain and complication rates in patients undergoing transperineal prostate biopsy? A prospective, randomized trial. Asian J Androl 2009;11:678–682.
5.
Inal GH, Oztekin VC, Uğurlu O, Kosan M, Akdemir O, Cetinkaya M: Sixteen-gauge needles improve specimen quality but not cancer detection rate in transrectal ultrasound-guided 10-core prostate biopsies. Prostate Cancer Prostatic Dis 2008;11:270–273.
6.
Trucchi A, De Nunzio C, Mariani S, Palleschi G, Miano L, Tubaro A: Local anesthesia reduces pain associated with transrectal prostatic biopsy. A prospective randomized study. Urol Int 2005;74:209–213.
7.
Chun FK, Epstein JI, Ficarra V, et al: Optimizing performance and interpretation of prostate biopsy: a critical analysis of the literature. Eur Urol 2010;58:851–864.
8.
Ficarra V, Martignoni G, Novella G, et al: Needle core length is a quality indicator of systematic transperineal prostate biopsy. Eur Urol 2006;50:266–271.
9.
Dindo D, Demartines N, Clavien PA: Classification of surgical complications: a new proposal with evaluation in a cohort of 6,336 patients and results of a survey. Ann Surg 2004;240:205–213.
10.
Ozden E, Göğüş C, Tulunay O, Baltaci S: The long core needle with an end-cut technique for prostate biopsy: does it really have advantages when compared with standard needles? Eur Urol 2004;45:287–291.
11.
Bostwick DG, Meiers I: Atypical small acinar proliferation in the prostate: clinical significance in 2006. Arch Pathol Lab Med 2006;130:952–957.
12.
Montironi R, Scattoni V, Mazzucchelli R, et al: Atypical foci suspicious but not diagnostic of malignancy in prostate needle biopsies (also referred to as ‘atypical small acinar proliferation suspicious for but not diagnostic of malignancy’). Eur Urol 2006;50:666–674.
13.
Fajardo DA, Epstein JI: Fragmentation of prostatic needle biopsy cores containing adenocarcinoma: the role of specimen submission. BJU Int 2010;105:172–175.
14.
Van der Kwast TH, Lopes C, Santonja C, et al: Guidelines for processing and reporting of prostatic needle biopsies. J Clin Pathol 2003;56:336–340.
15.
Ploussard G, Xylinas E, Salomon L, et al: The role of biopsy core number in selecting prostate cancer patients for active surveillance. Eur Urol 2009;56:891–898.
16.
Ghani KR, Dundas D, Patel U: Bleeding after transrectal ultrasonography-guided prostate biopsy: a study of 7-day morbidity after a six-, eight- and twelve-core biopsy protocol. BJU Int 2004;94:1014–1020.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.